Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REASCENT trial of anifrolumab in active systemic sclerosis
ISRCTN99067257Phase 2Recruiting
- Sponsor
- University of Leeds
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of anifrolumab in systemic sclerosis (SSc), sponsored by University of Leeds. Primary endpoint: Safety and tolerability. Started Sep 2025; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ISRCTN99067257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99067257.